A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337), a specific inhibitor of thymidylate synthase, was developed using protein structure-based drug design. Intravenously administered nolatrexed is active clinically. As oral b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1999
Assuntos:
Regular Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362691/
https://ncbi.nlm.nih.gov/pubmed/10070890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados